Trials / Completed
CompletedNCT03288727
Secondary Findings From High-throughput Sequencing: How to Announce Them With Respect to the Patient's Needs
Incidental Findings Produced by Diagnostic HTS: From the Needs of Patients to Organisational Considerations
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 342 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
High-throughput whole-genome sequencing (WGS) is bringing new opportunities in the diagnosis of rare diseases. It will more frequently lead to a primary diagnosis (aim of the genetic consultation), but it may also lead to the discovery of mutations not related to the patient's disease. These findings are called "incidental findings" (IF) and may give rise to preventive or curative interventions in a personalised medicine approach. The question of proposing to patients access to all or part of these findings is a matter of debate in France and elsewhere. This question has given rise to new challenges and new needs that professionals must respond to by implementing appropriate management and new skills. It raises specific ethical issues, which require precise understanding of the expectations and experiences of patients. Patients' diagnostic trajectories must also meet criteria for efficacy and financial and organisational sustainability for the healthcare establishments and, for the healthcare system. Our project aims to assess the expectations of patients/parents with regard to this opportunity, and to determine how information should be provided to patients and how they should be accompanied to ensure efficient and appropriate management.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | interviews with a psychologist | an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported. |
Timeline
- Start date
- 2017-11-13
- Primary completion
- 2021-11-24
- Completion
- 2021-11-24
- First posted
- 2017-09-20
- Last updated
- 2022-09-14
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03288727. Inclusion in this directory is not an endorsement.